Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
189
Stocks News & Analysis
stocks
Do AI labs like Anthropic and OpenAI have economic moats?
stocks
12 picks for an income portfolio - Q3 2026 update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.00 | 59.30 | 0.67% |
| CAC 40 | 7,803.33 | 73.64 | 0.95% |
| DAX 40 | 25,087.27 | 280.30 | 1.13% |
| Dow JONES (US) | 51,654.95 | 423.31 | 0.83% |
| FTSE 100 | 10,552.05 | 110.45 | 1.06% |
| HKSE | 24,249.18 | 37.83 | 0.16% |
| NASDAQ | 27,366.17 | 172.83 | 0.64% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,827.62 | 78.27 | 0.57% |
| S&P 500 | 7,811.54 | 46.18 | 0.59% |
| S&P/ASX 200 | 8,783.20 | 66.60 | 0.76% |
| SSE Composite Index | 3,792.26 | 21.53 | -0.56% |